GoPro Inc vs Zoetis Inc — how do they compare? GoPro Inc trades at $0.67 (market cap $122.03M), while Zoetis Inc trades at $77.25 (market cap $31.25B). The key difference: Zoetis Inc is far larger — about 256.1× GoPro Inc's market cap, and Zoetis Inc pays a 2.84% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| GPRO | ZTS | |
|---|---|---|
Market Cap | $122.03M | $31.25B |
Sector | Technology | Health |
52-Week High | $2.88 | $156.76 |
52-Week Low | $0.64 | $71.91 |
Enterprise Value | $169.98M | $38.54B |
Dividend Yield | — | 2.84% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Trailing returns across standard periods
Latest headlines on both assets
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →